GREGORY BAILEY

Gregory Bailey stands as a prominent figure in the biotechnology and life sciences investment landscape, recognized for his strategic vision and leadership in fostering innovative therapeutic companies. As the Chief Executive Officer of Relay Therapeutics, a clinical-stage precision medicine company, he guides the firm in leveraging its unique platform to discover and develop novel medicines for patients with unmet needs. His leadership at Relay Therapeutics exemplifies his commitment to advancing scientific breakthroughs into tangible patient benefits.

Beyond his executive role, Gregory Bailey is also a co-founder of MPM Capital, a leading venture capital firm dedicated to investing in life science companies. At MPM Capital, his investment focus is squarely on biotechnology and pharmaceuticals, particularly in areas such as oncology, rare diseases, and novel drug discovery platforms. He plays a crucial role in identifying promising early-stage companies and providing the strategic guidance and capital necessary for their growth and success. His involvement often extends to serving on the boards of portfolio companies, offering invaluable insights from his extensive industry experience.

Bailey's impressive career background underscores his deep expertise in both finance and the life sciences. Prior to co-founding MPM Capital, he held significant roles that shaped his understanding of the pharmaceutical industry's complexities. He served as a partner at BTG Pactual, a global investment bank, where he honed his financial acumen. His executive experience also includes serving as the Chief Financial Officer and a board member at BioMarin Pharmaceutical, a company focused on developing therapies for rare genetic diseases. He was also a board member at Medarex, a biopharmaceutical company known for its antibody discovery technology, which was later acquired by Bristol-Myers Squibb.

Throughout his career, Gregory Bailey has been instrumental in the success of numerous ventures. His notable investments and leadership contributions include his foundational role in Relay Therapeutics, as well as his involvement with companies like CoStim Pharmaceuticals (acquired by Amgen), Igenica (acquired by Shire), Potenza Therapeutics (acquired by Astellas), and TCR2 Therapeutics (acquired by Adaptimmune). These experiences highlight his consistent ability to identify high-potential companies and guide them through critical development stages, ultimately bringing innovative treatments closer to patients. His work reflects a steadfast dedication to pushing the boundaries of medical science and delivering transformative healthcare solutions.